Treatment for Wet Age-Related Macular Degeneration Receives Biologics License Application Approval

Officials with the FDA have accepted Novartis’ Biologics License Application (BLA) for brolucizumab (RTH258), a humanized single-chain antibody fragment (scFv), for the treatment of wet age-related macular degeneration (AMD), also known as neovascular AMD (nAMD).

Seeking to make brolucizumab available as quickly as possible, Novartis used a priority review voucher to expedite FDA review, according to the company. If approved by the agency, Novartis anticipates launching its brolucizumab product by the end of 2019.

"Reaching this milestone is an important step in our efforts to reimagine the treatment journey for people with wet AMD and their caregivers," said Fabrice Chouraqui, President, Novartis Pharmaceuticals Corporation, in a prepared statement. "We are looking forward to the potential of a new option for patients with wet AMD, who often have to navigate considerable physical and emotional difficulties caused by deteriorating vision."

Estimates suggest that by 2020, 1.5 to 1.75 million people in the U.S. will be living with wet AMD, a leading cause of blindness worldwide and a rapidly growing public health concern, according to Novartis. As the disease progresses, patients may experience loss of central vision, resulting in an inability to complete daily tasks. Without treatment, vision can rapidly deteriorate and may lead to blindness.

"Wet AMD robs people of their precious sight and takes a major toll on the lives of millions of people who face not only vision loss, but also the burden of frequent injections into their eyes," said Dawn Prall George, executive director, The Support Sight Foundation, in a prepared statement. "We are always excited about potential new treatment options and hopeful they may help people manage this devastating disease."

Novartis’ regulatory application is primarily based on Phase III data from the HAWK and HARRIER trials—prospective, randomized, double-masked multi-center studies. The primary endpoint of these studies was noninferiority to aflibercept in mean change in best-corrected visual acuity (BCVA) from baseline to week 48 (mean change in BCVA of 6.6 letters for brolucizumab 6 mg versus 6.8 letters for aflibercept in HAWK and 6.9 letters versus 7.6 letters, respectively, in HARRIER). HAWK and HARRIER are the first and only global head-to-head trials in patients with wet AMD that prospectively demonstrated efficacy at week 48 starting with a 12-week dosing regimen, according to Novartis.

Additionally, at week 48 in the studies, key secondary endpoint assessments showed significantly fewer brolucizumab patients with disease activity (23.5% of brolucizumab 6 mg patients versus 33.5% of aflibercept patients in HAWK, and 21.9% versus 31.4%, respectively, in HARRIER (P=0.0022 for both) as well as retinal fluid—key markers used by physicians to help guide management of the disease in clinical practice (31% fewer patients on brolucizumab 6 mg had intra-retinal fluid (IRF) and/or sub-retinal fluid (SRF) in HAWK, and 26% fewer in HARRIER, versus aflibercept (P<0.0001 for both).

Reference

Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD [news release]. East Hanover, NJ; April 15, 2019: Novartis. https://prnmedia.prnewswire.com/news-releases/novartis-announces-fda-filing-acceptance-and-priority-review-of-brolucizumab-rth258-for-patients-with-wet-amd-300832296.html. Accessed April 16, 2019.